Eltrombopag
- Generic Name
- Eltrombopag
- Brand Names
- Promacta, Revolade
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N4O4
- CAS Number
- 496775-61-2
- Unique Ingredient Identifier
- S56D65XJ9G
- Background
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...
- Indication
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
- Associated Conditions
- Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
- Associated Therapies
- First-line Therapy
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT01168921
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 12
- Registration Number
- NCT01133860
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria di Padova, Unità di Medicina Generale e Patologia Speciale, Padova, Italy
🇮🇹Fondazione IRCCS Policlinico San Matteo, Unità di Medicina III, Pavia, Italy
🇮🇹Policlinico Monteluce, Sezione di Medicina Interna e Cardiovascolare, Perugia, Italy
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 44
- Registration Number
- NCT01113502
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT01072162
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Promacta Pregnancy Registry
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01064336
Milk-only Lactation Study for Patients on Eltrombopag
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01055600
- Locations
- 🇺🇸
GSK Investigational Site, Research Triangle Park, North Carolina, United States
Eltrombopag for Post Transplant Thrombocytopenia
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT01000051
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT00996216
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2023-11-14
- Target Recruit Count
- 30
- Registration Number
- NCT00961064
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
- Conditions
- Interventions
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2020-10-20
- Target Recruit Count
- 43
- Registration Number
- NCT00922883
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.